RheumatologyAdvisor featuring Allan Gibofsky, MD, JD, MACR, FACP, FCLM

At this year’s European Alliance of Associations for Rheumatology (EULAR) Congress, held June 1 to 4 in Copenhagen, Hospital for Special Surgery (HSS) presented new research related to the treatment and management of rheumatoid arthritis …

Rheumatology Advisor featuring Allan Gibofsky, MD

Healio Rheumatology featuring Allan Gibofsky, MD

The Rheumatologist featured HSS rheumatologist Allan Gibofsky, MD, in an article about how to help patients with medication costs. "Not infrequently, patients will ask if a drug is covered by their formulary. When I make a drug decision, I may find …

Healio Rheumatology featured HSS rheumatologist Allan Gibofsky, MD, in an article about access to biosimilars for patients. "It is a major concern that the potential benefits of biosimilar medications have not been trickling down to patients," said …

Rheumatology Advisor interviewed HSS rheumatologist Allan Gibofsky, MD, about the potential financial benefits of switching stable patients with a rheumatic disease from an originator biologic to a biosimilar. "If a patient is stable on a …

HSS rheumatologist Allan Gibofsky, MD, discussed how disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA) affect a patient's vulnerability to infection for Rheumatology Advisor. "Many of the DMARDs and biologic agents used …

Healio Rheumatology reported that the FDA rejected the approval of a biopharmaceutical company's biologics license applications. HSS rheumatologist Allan Gibofsky, MD, noted that this rejection demonstrates the careful scrutiny that the FDA applies …

As biosimilar therapies for rheumatologic conditions are approved in the U.S., HSS rheumatologist Allan Gibofsky, MD discussed the perception and potential pricing of biosimilars in the print cover story of Healio Rheumatology. According to the …